Maintenance of the osmobalance is important for life. In this process, in which brain and kidney act in concert, mammals have to cope with significant deviations as drinking water reduces plasma osmolality, whereas salty food increases it. To restore homeostasis, specialized nuclei within the hypothalamus play a pivotal role in detecting changes in plasma osmolality and initiating appropriate responses. These responses are accomplished by either changing the intake of water or the excretion of water by the kidney. In the past decade, several novel findings have made significant contributions to our insights in the process of systemic osmoregulation. Novel proteins have been identified in the brain as well as in the kidney that are fulfilling important roles in the process of systemic osmoregulation. In this review, recent evidence of the involvement of TRPV channels (TRPV1, TRPV2, and TRPV4) and proteins, such as sodium channels NALCN and Na x , in neuronal osmoregulation, as well as; e.g., the purinergic P2Y2 receptor in renal osmoregulation, are discussed, and integrated with existing knowledge of systemic osmoregulation. For mammals, the osmotic set point of the blood is ϳ290 mosmol/kg (1). This value, however, is continuously challenged during daily life, as we lose water through breathing, perspiration to maintain body core temperature, defecation, and urine production to remove body waste products. Most biological membranes are semipermeable, meaning that water can move freely over these membranes, whereas solutes cannot. Therefore, in states of increased blood sodium concentration (hypernatremia), which occurs with states of water loss as above, water leaves the cell, causing cellular dehydration and cell shrinkage. In contrast, in states of reduced blood sodium concentration (hyponatremia), water moves from blood into the, cells thereby causing cell swelling. As both cell shrinkage and cell swelling have major implications for normal cell function, our body is equipped with a well-developed osmoregulatory mechanism to minimize changes in blood osmolality, which is highly sensitive, because changes as small as 1-3% from the set point are directly initiating responses to correct these disturbances (2, 3). This regulation of plasma osmolality is achieved by controlling the intake of water, mediated by behavioral responses, such as thirst, and by controlling the amount of water excreted by the kidneys, which mainly depends on the central release and renal action of the antidiuretic hormone arginine vasopressin (AVP; Fig. 1 ).
For mammals, the osmotic set point of the blood is ϳ290 mosmol/kg (1) . This value, however, is continuously challenged during daily life, as we lose water through breathing, perspiration to maintain body core temperature, defecation, and urine production to remove body waste products. Most biological membranes are semipermeable, meaning that water can move freely over these membranes, whereas solutes cannot. Therefore, in states of increased blood sodium concentration (hypernatremia), which occurs with states of water loss as above, water leaves the cell, causing cellular dehydration and cell shrinkage. In contrast, in states of reduced blood sodium concentration (hyponatremia), water moves from blood into the, cells thereby causing cell swelling. As both cell shrinkage and cell swelling have major implications for normal cell function, our body is equipped with a well-developed osmoregulatory mechanism to minimize changes in blood osmolality, which is highly sensitive, because changes as small as 1-3% from the set point are directly initiating responses to correct these disturbances (2, 3) .
This regulation of plasma osmolality is achieved by controlling the intake of water, mediated by behavioral responses, such as thirst, and by controlling the amount of water excreted by the kidneys, which mainly depends on the central release and renal action of the antidiuretic hormone arginine vasopressin (AVP; Fig. 1 ).
CENTRAL OSMOREGULATION
In states of hypernatremia, so-called osmoreceptors located in specialized nuclei in the brain are activated due to cellular dehydration and give rise to action potentials, eventually leading to a thirst sensation and to depolarization of AVP-producing magnocellular neurons located in the supraoptic nucleus (SON). The first evidence that the brain possesses an intrinsic osmosensor came from early studies that demonstrated that infusions of hyperosmotic solutions of sodium chloride or sucrose, but not of urea, inhibit renal water excretion in conscious water-loaded dogs (4) . The observation that the hypertonic solutions sodium chloride and sucrose caused an inhibition of the water excretion provided the first information about the localization of these osmoreceptors: sodium chloride, sucrose, and urea can hardly penetrate the blood brain barrier; therefore, all three will give rise to cellular dehydration in cells behind the blood brain barrier. However, in regions that lack the blood brain barrier, cells are permeable to urea, but not to sodium, chloride, or sucrose. As infusions of sodium chloride and sucrose did result in antidiuresis, while urea was ineffective, the researchers concluded that the osmoreceptor-containing cells should be in brain regions outside the blood brain barrier (4 -7) . This hypothesis was supported by immunohistochemical studies that revealed that in water deprived rats, c-fos expression, a marker for activated neurons, was increased in the three brain nuclei associated with the lamina terminalis and located outside the brain barrier:, the subfornical organ (SFO), the median preoptic nucleus (MnPO), and the organum vasculosum lamina terminalis (OVLT) (refs. 8, 9 and Fig. 2) . Moreover, functional magnetic resonance imaging studies revealed increased neural activity in the anterior region of the third ventricle, where the SFO, MnPO, and OVLT reside, during hypertonicity in animals (10) and humans (11) . In addition, lesion of these three brain nuclei interfered with osmotically evoked osmoregulatory responses, such as drinking and the release of AVP (12) . Like antidiuretic responses, it has been shown that drinking responses cannot be evoked by hypertonic urea solutions, indicating that the central osmoreceptors regulating thirst are also located in brain regions outside the blood brain barrier (13) . Robertson et al. (14) found that the plasma osmolality threshold for AVP release is 281.3 mosmol/kg in which urine is maximally diluted, and that an increase in plasma osmolality to 294 mosmol/kg resulted in a maximal antidiuretic response. Interestingly, 294 mosmol/kg was also the plasma osmolality at which healthy adults first report a conscious desire to drink, indicating that the threshold for AVP release and thirst sensation are different and that thirst functions as a backup protection in case the renal response is not capable of maintaining homeostasis (14) . Although the threshold for AVP release and Figure 1 . Regulation of osmobalance. Blood osmolality is ϳ 290 mosmol and varies within a narrow range of 1-2%. With some loss of water, the increased osmolality stimulates central osmoreceptors located in specialized nuclei outside the blood-brain barrier. Activated osmoreceptors lead to a thirst sensation and to the release of the antidiuretic hormone arginine vasopressin (AVP). Thirst-induced drinking and AVP-induced water reabsorption in the kidney lead to a correction of the osmobalance. thirst differ, and some dissimilarities in the regulation have been described, the control of AVP release and thirst are generally considered to be very similar, if not identical (15) .
To date, several thirst-modulating hormones have been described. The most extensively studied hormone shown to exert a dipsogenic effect in animals is angiotensin II (16) . This dipsogenic action of angiotensin II is thought to be mediated by the SFO, because the SFO contains a high concentration of the angiotensin AT 1 receptor (17) and ablation of the SFO completely abolished the dipsogenic response to angiotensin II (18) . In addition, relaxin, a peptide hormone secreted by the corpus luteum during pregnancy, has been found to directly stimulate SFO neurons to generate a thirst response (19) . The atrial natriuretic peptide (ANP), which is released by cardiac myocytes in states of hypervolemia, has been shown to inhibit osmotically induced as well as angiotensin II-induced water intake in rats (20) .
CENTRAL OSMOREGULATION BY OSMOSENSITIVE NEURONS
It is now well established that neurons as well as surrounding glia cells of these nuclei are involved in the initiation of the central osmotic response. Using state-of-the-art in vivo electrophysiological techniques, Bourque et al. (12) were able to show hypertonicityinduced increases in the number of action potentials not only in neurons of slices of the SFO, OVLT, and MnPO (12) but also in acutely isolated neurons from the SFO (12; 21), MnPO (12) , and OVLT (12, 22) . As acutely isolated neurons lack surrounding glia cells, these latter data revealed that the neurons of the SFO, MnPO, and OVLT are intrinsically sensitive to changes in osmolality. Further studies demonstrated that the MnPO, OVLT, and SFO have projections to neurons in the SON (9, 23) and the paraventricular nucleus (PVN) in the hypothalamus (24) and that local hypertonicity in the OVLT increases the firing rate recorded in SON neurons (25) .
MODULATION OF CENTRAL OSMOREGULATION BY GLIA CELLS
Besides neurons, evidence has accumulated that glia cells of the osmosensitive nuclei also have important roles in central osmoregulation. Glia cells in all osmosensitive regions have been shown to accumulate high concentrations of the amino acid taurine, which is released during hyponatremia in vivo (ref. 26 and Fig. 3 ). In the SON, taurine has subsequently been shown to bind and activate glycine receptors on magnocellular neurons and mediate the influx of chloride ions, leading to a reduction in the firing rate of these neurons (27, 28) . Surprisingly, however, taurine release from glia cells occurs independently of extracellular Ca 2ϩ and Na ϩ , and does not involve the taurine transporter, but is still released in an osmodependent manner (29, 30) . Taken together, these data indicate that taurine release from glia cells contributes to the osmosensitivity of SON neurons, implicating an active participation of glia cells in osmoregulation.
The physiological relevance of these findings in central osmoregulation, however, remains uncertain, because as mentioned earlier, systemic osmotic changes do not lead to osmotic changes in the SON. At present, therefore, it is unknown whether neurons in the primary osmosensing brain nuclei, such as OVLT or SFO, are also regulated by taurine.
NOVEL PLAYERS IN CENTRAL OSMOREGULATION
Although the brain nuclei involved in central osmoregulation have been identified, little is known about the proteins that play a role in the process of osmosensing. Only recently, the first proteins involved in this process have been identified (Fig. 3 ). The first evidence about the molecular identity of some of these proteins came from studies in the osm-9 gene mutant line of the worm Caenorhabditis elegans. In this mutant line, the normal avoidance response to high osmolality was absent (31) . The osm-9 gene encodes a member of the superfamily of transient receptor potential (TRP) channels and, most interestingly, expression of mammalian transient receptor potential vanilloid (TRPV)4 in the ciliated sensory neurons of osm-9 mutant worms restored avoidance responses to hypertonicity (31) . Interestingly, earlier and later studies supported involvement of TRP channels in SON and OVLT osmosensing, because sensing was lost on incubation with TRP channel inhibitors gadolinium or ruthenium red (32) (33) (34) (35) .
To investigate the role of TRPV4 in osmosensory transduction, two research groups created TRPV4-knockout (KO) mice, but obtained different results. Mizuno et al. (36) found no difference in water intake behavior, serum osmolality, or serum AVP levels at basal conditions, but after increasing the serum osmolality by means of intraperitoneal propylene glycol injections, these animals displayed an exaggerated AVP response. Therefore, the researchers concluded that TRPV4 plays an inhibitory role in AVP secretion (36) . In the study of Liedtke et al. (37) , however, TRPV4-KO mice drank less water and were hyperosmolar, and plasma levels of AVP were decreased as compared to wild-type mice, suggesting an impairment of osmotic sensing in the CNS of the TRPV4 Ϫ/Ϫ mice (37). Taken together, these studies demonstrate an involvement of TRPV4 in osmoregulation, but how it is involved remains unclear. Possibly, proper analysis of the osmoregulatory role of TRPV4 KO is complicated by the finding that TRPV4 is expressed in brain as well as the kidney (38) .
TRPV1 is expressed in OVLT as well as the SON, and TRPV1-KO mice displayed a pronounced serum hyperosmolality under basal conditions and impaired AVP responses to osmotic stimulation (32, 35) . Furthermore, TRPV1-KO mice showed an attenuated water intake in response to systemic hypertonicity as compared to wild-type mice (32) . Using isolated OVLT or SON neurons, it was found that the TRPV1-KO mice lacked the osmosensory signal transduction cascade normally observed (32, 35) . These studies clearly suggested to an important role of TRPV1 in the osmosensory transduction pathway. A recent study by Taylor et al. (39) , however, reported no difference in water intake between these animals and found similar Fos immunoreactivity in the osmosensitive nuclei of wildtype and TRPV1
Ϫ/Ϫ mice after acute and chronic increases in plasma osmolality. Therefore, further studies are needed to clarify the role of TRPV1 in central osmoregulation.
Recently, a nonselective cation channel, named NALCN, has been shown to be involved in osmoregulation (40) . Haplotype association mapping in different mouse strains revealed that single-nucleotide polymorphisms within the NALCN gene correlated with differences in serum sodium levels. This association was confirmed by the finding that mice heterozygous for and with reduced expression of NALCN displayed an increased serum sodium concentration as compared to wild-type littermates. As NALCN is expressed mainly in the brain, where it sets the neuronal membrane potential (41), an interesting hypothesis for its role in osmoregulation may be that hyperpolarization of osmosensitive neurons due to decreased NALCN expression reduces hypertonicity-induced calcium influx via TRPV1 or TRPV4, resulting in a reduced frequency of action potentials. Indeed, calcium influx via TRPV4 and TRPV1 has been shown to be membrane potential dependent (42, 43) . Although NALCN has been identified as a novel player in osmoregulation, the precise role of NALCN in osmoregulation remains to be established.
While the proteins above are thought to have a role in regulating the osmosensitive neurons themselves, also proteins have been identified that may modulate the osmosensitive function of glia cells. One such protein is dystrophin 71, which is expressed in glia cells in the SON. Mice lacking the dystrophin 71 gene displayed a lower plasma osmolality and an increased amount of AVP peptide in the SON as compared to wild-type littermates. This was maintained after salt loading and suggested a role for dystrophin 71 in the establishment of the osmotic set point (44) . Since dystrophin 71 is produced in glia, but not in magnocellular neurons, of the SON, dystrophin 71 is suggested to be involved in the intrinsic osmosensitivity of perivascular glia cells of the SON (Fig. 3) . However, its involvement in osmosensitivity largely depends on whether dystrophin 71 is expressed in the primary osmosensing brain nuclei, such as OVLT and/or SFO. Therefore, these data suggest that dystrophin 71 may be involved in modulating the osmosensory transduc-tion pathway; however, its precise role in central osmoregulation remains to be determined.
Another protein likely involved in central osmomodulation by glia cells is the Na x protein. This protein was recently shown to be expressed in glia cells of both SFO and OVLT, where it senses extracellular sodium and transduces changed sodium levels to surrounding neurons by releasing lactate (45) . By an unknown mechanism, the released lactate is thought to increase the osmoneuronal firing rate, because deletion of the Na x -positive regions in the hypothalamus due to a developed autoimmune reaction against Na x led to essential hypernatremia (46) . While this study nicely illustrates the importance of the involvement of Na x and glia cells in central osmoregulation, Na x -deficient mice displayed a normal AVP response to dehydration, indicating that osmotic induction of AVP release still occurs independent of Na x -mediated sodium sensing and also illustrates the modulating function of glia cells in central osmoregulation (ref. 47 and Fig. 3 ).
POTENTIAL INVOLVEMENT OF OTHER PLAYERS IN CENTRAL OSMOREGULATION
While strong evidence indicates that TRPV1 and TRPV4 are involved in osmoregulation, other members of the TRP family may also be involved. TRPV2 and TRPV1 are coexpressed in SON neurons and can form heterotetramers in vitro, and TRPV2 is activated by hypotonicity when heterologously expressed (35, 48 -52) . If heterotetramerization also occurs in vivo, a different composition of TRPV1 and TRPV2 proteins in TRPV1/2 tetrameric complexes may exert different osmo-induced calcium influxes and therewith variations in the release of AVP.
A similar role has been suggested for TRPA1. Indeed, TRPA1 is activated by mild hypertonicity in HEK293 cells and colocalizes with TRPV1 in trigeminal sensory neurons (53, 54) . When it is also expressed in and heteromerizes with TRPV1 or TRPV4 in osmosensitive nuclei, TRPA1 may also modulate their activity in osmoregulation. Their possible physiological role in central osmoregulation, however, awaits further studies.
Already in 1994, Peter Agre and colleagues proposed that aquaporin-4 (AQP4), expressed in glia cells, could represent the osmoreceptor regulating body water balance and mediating water flow in the central nervous system (55, 56) . Interestingly, recent data reveal that AQP4 interacts with TRPV4 and that this complex is essential for cell volume control in astrocytes. However, although this study clearly indicates a role for AQP4 in regulated volume decrease in astrocytes, AQP4-KO mice have a normal serum osmolality (57) , providing evidence against a role for AQP4 in central osmoregulation (58).
RENAL OSMOREGULATION
AVP, released from the pituitary into the bloodstream with hypernatremia, traverses to the kidney, where it binds its vasopressin V2 receptor (V2R), located in the basolateral membrane of principal collecting duct cells (Fig. 4) . This activation of the V2R will initiate a cAMP signal transduction cascade, which will eventually lead to phosphorylation of AQP2 water channels at Ser256. On this phosphorylation of AQP2 and of other proteins, AQP2 is translocated from intracellular storage vesicles to the apical plasma membrane, increasing the water permeability of the principal cells (59) . This increase in water permeability facilitates water reabsorption in these cells, since water can now enter the cell through AQP2 along the osmotic NaCl and urea gradient and leave the cell through water channels AQP3 and AQP4. These channels are constitutively expressed in the basolateral membrane, and via this mechanism urine becomes concentrated. Once isotonicity has been restored, the osmosensitive neurons will no longer be activated, which results in lower AVP levels. Subsequently, reduced blood AVP levels will lead to internalization of AQP2 from the apical membrane and reduced water reabsorption.
NOVEL PLAYERS IN RENAL OSMOREGULATION
While the roles of AVP, V2R, and AQP2 are firmly established (60 -62) , recent studies revealed several novel molecular players involved in renal osmoregulation. An interesting novel molecular player in renal osmoregulation is the P2Y2 receptor, encoded by the P2y2r gene. P2y2r, located on chromosome 7, encodes the P2Y subtype of purinergic receptors and has been linked to hypertension in Japanese men (63) . Indeed, it has been shown that mice lacking the P2y2r gene display an increased urinary concentration due to a higher AQP2 protein expression despite similar serum osmolality and AVP levels, and develop a salt-resistant arterial hypertension (64, 65) . More recently, it was shown that dDAVP treatment of mouse collecting duct (mpkCCD) cells caused P2Y2R translocation to the apical and basolateral membrane, and that activation of exogenous P2Y2R in Xenopus oocytes decreased membrane AQP2 expression and AQP2-mediated water permeability (66) . In the same cells, Boone et al. (67) recently showed that ATP reduces AQP2 expression by increasing its ubiquitin-dependent internalization and lysosomal degradation and by decreasing AQP2 gene transcription via reducing AVP-induced cAMP levels. Taken together, these results indicate that purinergic signaling does play an important role in regulating AVP-dependent water transport in mice (Fig. 4) .
Recently, it has been shown that mice conditionally lacking the ItgbI gene, encoding ␤-integrin, in the kidney collecting duct from embryonic day 9.5 onwards suffered from progressive renal dysfunction and polyuria (68) . Integrins are cell adhesion molecules that are involved in cell-cell and cell-matrix interactions that control many aspects of cell behavior. such as migration, proliferation, survival, and differentiation (69). Wu et al. (68) reported that mice lacking the ItgbI gene displayed a decreased medullary collecting duct expression of V2R and AQP2 and it was suggested that the ItgbI gene plays a pivotal role in the development, formation and maintenance of the renal collecting system. Although this study nicely illustrates the importance of ␤-integrin in the development of the collecting duct, it remains to be established whether ␤-integrin is indeed involved in osmoregulation in a fully differentiated collecting duct system.
PATHOPHYSIOLOGY OF THE HUMAN OSMOREGULATION
Disturbances of osmoregulation in humans manifest themselves as a change in serum sodium concentrations and will thus result in either hypernatremia, defined as an increase in serum sodium concentration above 145 mM, or hyponatremia, defined as a decrease in the serum sodium concentration below 136 mM. Hypernatremia is a common electrolyte disorder and frequently develops as an iatrogenic condition. It represents a deficit of water in relation to sodium, and although it can be due to a gain of sodium, the majority of cases are due to a loss of water exceeding the loss of solutes, caused by insufficient water intake or excessive water excretion. Disorders causing hypernatremia are those associated with either impaired water intake, inadequate AVP release, or an inability of the kidney to respond to AVP.
Symptoms of hypernatremia are mostly reflected by a dysfunction of the central nervous system and are more severe when the increase in serum sodium concentration is large and occurs rapidly (over a period of hours). Hypernatremia as an increase in serum osmolality of ϳ10 mosmol/kg due to fluid restriction, which corresponds with a volume loss of 1.4 L of the 42 L body fluid of a person of 70 kg, has been reported to cause feelings of headache, reduce levels of alertness, and reduce the ability to concentrate among healthy subjects (70) . Furthermore, it has been shown that the level of consciousness in elderly hospitalized patients is Figure 4 . Regulation of AQP2-mediated water transport in the principal cell of the collecting duct. On binding of AVP to its V2R in the renal collecting duct, its activation initiates a cAMP signaling cascade, leading to AQP2 phosphorylation and its translocation toward the apical membrane. AQP2 insertion allows cellular water entry, which will exit the cell via AQP3 and AQP4 in the basolateral membrane, and will lead to concentrated urine. Besides this fast response, cAMP will lead to increased AQP2 gene transcription. Possible novel players in renal osmoregulation are depicted. See text for details.
correlated with the severity of hypernatremia (71) . More severe hypernatremia-induced brain shrinkage can cause vascular rupture, with cerebral bleeding, subarachnoid hemorrhage, and permanent neurological damage or death (72) .
Hyponatremia represents an excess of water relative to sodium, and it can be due to a primary increase in water intake or reabsorption, possibly combined with secondary sodium depletion (dilutional hyponatremia). Hyponatremia can occur acutely or can be present chronically. Acute hyponatremia is a severe condition that can lead to cerebral edema and is associated with up to a 7-fold higher mortality.
Chronic hyponatremia is the most common electrolyte disturbance in hospitalized patients (73, 74) but is considered a comorbid condition requiring supportive treatment only. Recent studies, however, indicate that chronic hyponatremia is associated with attention deficits, gait disturbances, falls, and fractures (75, 76) . Furthermore, it has been shown that hyponatremia is a risk factor for osteoporosis, myocardial infarction, and overall mortality independent of possible confounders. This was confirmed in a rat model for chronic hyponatremia, where it was shown by analysis of excised femurs, using dual-energy X-ray absorptiometry, that hyponatremia for 3 mo significantly reduced bone mineral density by ϳ30% as compared with normonatremic control rats (77, 78). The above-mentioned studies clearly show that hypernatremia and hyponatremia are important problems, not only in hospitalized patients but also in the general population, and illustrate the broader importance of maintenance of a proper osmobalance. Disturbances in the osmobalance can be a direct problem in osmoregulation or indirectly through a change in volume regulation. Since there are excellent reviews about the volume-induced disturbances in osmoregulation (79, 80) , we will focus on the direct disturbances in osmoregulation.
OSMOREGULATORY DISORDERS LEADING TO HYPERNATREMIA
A disorder of this category that is well studied is diabetes insipidus (DI), a disease in which AVP secretion (central DI) or the renal effects of AVP (nephrogenic DI) are impaired without an abnormality of thirst sensation. Patients with DI cannot concentrate their urine, resulting in polyuria and, consequently, polydipsia. Central DI can result from various acquired or congenital anatomic lesions that disrupt the hypothalamic posterior pituitary axis, including surgery, tumors, trauma, hemorrhage, thrombosis, infarction, or granulomatous disease (81) . Besides lesions, central DI can also be of congenital origin, caused by mutations in the AVP gene resulting in nonfunctional AVP and, consequently, an inability to reabsorb water from the prourine (82) .
Nephrogenic DI is characterized by the inability to concentrate urine, despite increased levels of functional AVP, and can be congenital as well as acquired. Congenital NDI can be due to defects either in the gene encoding the V2-receptor or in the gene encoding the AQP2 water channel, revealing the essential role of these genes in AVP-induced water reabsorption (83) . Acquired nephrogenic DI can be secondary to hypokalemia, hypercalcemia, and urinary tract obstruction or can be drug-induced such as with lithium treatment in patients treated for bipolar disorders. Both acquired and congenital NDI and their molecular causes are nicely reviewed elsewhere (84) . In case of insufficient supply of water, these humans are hypernatremic. A separate group of disorders, which are characterized by inappropriate lack of thirst despite increased plasma osmolality and mild hypovolemia, were previously named "adipsic hypernatremia" or "essential hypernatremia" and can be grouped as disorders of osmoreceptor function. Although this group of disorders is uncommon, four different patterns of osmoreceptor dysfunction were discriminated (81) . The first group displays a blunted AVP and thirst response to osmotic stimulation due to decreased sensitivity of the osmosensitive brain regions. The recently identified patient with hypernatremia due to an autoimmune reaction against the Na sensor Na x is of this category (46) . The second group displays complete destruction of the osmosensitive brain regions. In most cases, structural abnormalities in the hypothalamic-pituitary area are the cause of this disorder. Patients have no AVP secretion or thirst response regardless of their plasma osmolality. The third group of osmoreceptor dysfunction is a consequence of an upward resetting of the osmostat. In this condition, AVP and thirst response itself are normal but do not occur until higher plasma osmolalities have been reached. The last group is characterized by a selective dysfunction of thirst regulation with intact AVP secretion (81) . At present, there are several patients with persistent hypernatremia, but without any hypothalamic structural lesions, the molecular cause of which remains to be established (85) (86) (87) (88) (89) (90) .
OSMOREGULATORY DISORDERS CHARACTERIZED BY HYPONATREMIA
The most common form of hyponatremia, dilutional hyponatremia, is caused by an impairment in renal water excretion. In most situations, this is due to high plasma concentrations of AVP, despite hypotonicity. This so-called syndrome of inappropriate secretion of antidiuretic hormone (SIADH) is often due to osmoinsensitive AVP production from tumors or to a variety of drugs (91) . Recently, excessive antidiuresis due to a renal problem was identified and therefore named the nephrogenic syndrome of inappropriate antidiuresis (NSIAD; ref. 92) . Here, two infants were described whose clinical and laboratory evaluations were consistent with the presence of SIADH, yet who had unde-tectable AVP levels. DNA sequencing of each patient's V2R gene (AVPR2) identified missense mutations in both, which caused constitutive activation of the receptor.
Besides central and nephrogenic DI, which result in hypernatremia, a third DI variant exists, which is called dipsogenic DI. Dipsogenic DI is often psychogenic in origin, and psychotic patients treated with antidiuretics to correct for the polyuria often run into hyponatremia because of the continuation of polydipsia (93) . Whether the polydipsia in psychotic patients is due to a lesion in osmoreceptor function or whether it has a habitual cause remains to be elucidated.
To further emphasize the role of TRPV4 as novel player in osmoregulation, it was recently shown that a nonsynonymous polymorphism in the TRPV4 gene was significantly associated with hyponatremia in two non-Hispanic Caucasian male populations. It was suggested that the loss-of-function TRPV4 polymorphism reduced the hypothalamic osmotic set point, resulting in inappropriate release of AVP, and explaining the hyponatremia correlated with this variant (94) . However, since TRPV4 has been shown to be expressed in kidney as well as in the osmosensory brain regions, such as OVLT and SFO (38) , its precise role in osmoregulation and how this loss-offunction polymorphism can lead to hyponatremia awaits further investigation.
The other possible mechanism for development of hyponatremia is by solute depletion, which is primarily due to a decrease in total body solute together with secondary water retention. The use of diuretics is the most common cause of hypovolemic hyponatremia. More specifically, thiazides are more commonly associated with severe hyponatremia than are loop diuretics, such as furosemide (95) . An overview of the causes of hyponatremia is presented in Table 1 .
CONCLUSIONS
The past decade has resulted in several exciting discoveries in integrative osmoregulation, of which identification of the first molecular players in, especially, central osmoregulation were the highlights. It is now clear that TRPV channels play a major role in osmoregulation of central neurons and that the Na x protein plays an important role in central osmoregulation by supporting glia cells, thereby providing strong molecular evidence of the role of glia cells in central osmoregulation. In the renal part of osmoregulation, the identification that not only extensive loss but also extensive reabsorption of water from prourine can be caused by mutations in the V2R, and that renal water reabsorption is modulated by other factors, such as ATP via P2Y2 receptors and, likely, polarization, has brought us new insight into the diverse ways in which renal water uptake can be changed. The challenge of the future now is to understand the precise roles of the newly identified proteins in regulating the osmobalance and, concerning the disorders, how we can make use of the obtained knowledge to correct the disturbances. In this latter aspect, the identification of cell-permeable V2R agonists to circumvent congenital NDI by activating functional, but ER-retained, V2R mutants inside the cell is one of the promising directions for therapy (96) . 
